Peptech Limited focuses on the research and development of peptides and proteins in the areas of human pharmaceuticals and animal health. Peptech holds a 36.1 per cent shareholding in Domantis, a UK-based drug development company, and has formed a 50/50 joint venture company with Biosceptre. The company is positioned to become a globally recognised leader in biopharmaceutical development. For more information, please visit www.peptech.com.

	Principal Sector	Advertising & Media
	Principal Industry	None
	Homepage	www.peptech.com

Stock Exchange Stock Code   ASX:PTD PTD

Aust Business Headlines, (ASX: JBM), (ASX: PSV), (ASX: PTD) (OCT 29, 2007)

Aust Market Wrap, (ASX: PTD), (ASX: EGX), (ASX: IAG), (ASX: OXR), (ASX: OXR), (ASX: SEV), (ASX: QAN), (ASX: CAA), (ASX: GBG) (JULY 9, 2007)

Peptech Partner Biosceptre Granted Patent for Cancer Target (JUNE 27, 2005)

Peptech ASX: PTD - Shareholders Approve Peptech-Evogenix Merger - Dr John Chiplin, CEO (AUG 9, 2007)

Peptech ASX: PTD - Peptech Presentation To Eg Capital Forum - Dr John Chiplin, CEO (JULY 12, 2007)

Peptech ASX: PTD - Merger Roadshow Presentation - Dr John Chiplin, MD; Dr Phil Jennings, Exec. Director and Dr Cliff Holloway, VP of Bus. Development (JUNE 6, 2007)

Peptech ASX: PTD - Enters Phase I Clinical Trials - Dr Phil Jennings, Executive Director (MAY 22, 2007)

Peptech ASX: PTD - Record Profit for Half Year - Dr John Chiplin, MD (MAY 17, 2007)

Peptech ASX: PTD - Peptech & EvoGenix Merge to Form Antibody Powerhouse - Dr John Chiplin and Dr Merilyn Sleigh (MAY 7, 2007)

Peptech ASX: PTD - Suprelorin Recommendation Clears Path for Sales in Europe - Dr Paul Schober, General Manager, Peptech Animal Health (MAR 21, 2007)

Peptech ASX: PTD - Appoints Global Financial Adviser to Examine Strategic Options - Dr John Chiplin, CEO (MAR 14, 2007)

Peptech ASX: PTD - Company Update - Dr Cliff Holloway, Vice President, Business Development (FEB 9, 2007)

Peptech ASX: PTD - Domantis Sale and AIM Listing - Dr John Chiplin, CEO (DEC 21, 2006)